Document Detail


Chemokine receptors--future therapeutic targets for HIV?
MedLine Citation:
PMID:  9952309     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To date, triple drug therapies for HIV have resulted in spectacular reductions in the number of virus particles and often remarkable recovery from disease in infected people. There is still, however, a great need for improved therapies. A battery of drugs aimed at different stages in the life cycle of HIV will enable switching of treatments if resistant viruses emerge or if patients are unable to tolerate particular therapies. Intense efforts are now underway to produce drugs that target chemokine receptors used by HIV to gain entry into cells. HIV needs two receptors on the host cell surface for efficient attachment and infection. HIV first interacts with CD4 but requires a coreceptor to penetrate the cell membrane. The first coreceptor, identified in 1996, is a member of the family of chemokine receptors, members of the G-protein coupled 7TM superfamily, which are involved in the trafficking of leukocytes in immune surveillance and inflammation. Such a therapeutic approach would differ from those used successfully to date, which focus largely on proteins coded by the HIV virus itself, and which are required for the replicative cycle of the virus. Many small, orally bioavailable molecules that block various 7TM receptors are used to treat a panoply of diseases including ulcers, allergies, migraines, and schizophrenia. These molecules are the cornerstone of the pharmaceutical industry's contribution to the fight against so many diseases, and it is hoped that a small molecule inhibitor of coreceptors can be developed that will become an invaluable drug in the fight against AIDS.
Authors:
A E Proudfoot; T N Wells; P R Clapham
Related Documents :
2235989 - Identification of human immunodeficiency virus in the heart of a patient with acquired ...
9824319 - Comparison of seven quantitative assays to assess lymphocyte cell death during hiv infe...
15622449 - Dendritic cell numbers in the blood of hiv-1 infected patients before and after changes...
18547629 - Pathogenic mechanisms of b-lymphocyte dysfunction in hiv disease.
8901429 - The effect of azt on dendritic cell number and provirus load in the peripheral blood of...
16842879 - Hiv infection of mononuclear cells is calcium-dependent.
9697719 - Emergence of syncytium-inducing human immunodeficiency virus type 1 variants coincides ...
18097109 - Miliary tuberculosis in human immunodeficiency virus infected patients not on antiretro...
16506089 - Liver abscess that responded well to pazufloxacin therapy.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Biochemical pharmacology     Volume:  57     ISSN:  0006-2952     ISO Abbreviation:  Biochem. Pharmacol.     Publication Date:  1999 Mar 
Date Detail:
Created Date:  1999-02-19     Completed Date:  1999-02-19     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0101032     Medline TA:  Biochem Pharmacol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  451-63     Citation Subset:  IM; X    
Affiliation:
Serono Pharmaceutical Research Institute, Geneva, Switzerland. Amanda.proudfoot@serono.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acquired Immunodeficiency Syndrome / drug therapy
Anti-HIV Agents / chemical synthesis*,  therapeutic use
Chemokines / chemistry
Drug Design
HIV
HIV Infections / drug therapy*
Humans
Models, Molecular
Protein Conformation
Receptors, Chemokine / chemistry,  physiology*
Receptors, HIV / chemistry,  physiology
Viral Proteins / chemistry
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/Chemokines; 0/Receptors, Chemokine; 0/Receptors, HIV; 0/Viral Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Does fractionation decrease the risk of breast cancer induced by low-LET radiation?
Next Document:  Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed...